# Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

> **NCT06262139** · PHASE1,PHASE2 · RECRUITING · sponsor: **Songqi Gao** · enrollment: 12 (estimated)

## Conditions studied

- MRI Scan

## Interventions

- **DRUG:** MT218 injection

## Key facts

- **NCT ID:** NCT06262139
- **Lead sponsor:** Songqi Gao
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-25
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06262139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06262139, "Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06262139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*